Efficacy of Omalizumab, Dupilumab, and Remibrutinib in Chronic Spontaneous Urticaria: Phase Data and Placebo Response

Documenti analoghi

• Physical Exercise Improves Symptomatic Dermographism
  di: Ragıp Ertaş, et al.
  Pubblicazione: (2025)
• Lymphopenia in Chronic Spontaneous Urticaria is Linked to Basopenia and Eosinopenia
  di: Mojca Bizjak, et al.
  Pubblicazione: (2024)
• Perceived Acquired Resistance to Omalizumab in Obese Patients With Chronic Spontaneous Urticaria
  di: Francisco Martins, et al.
  Pubblicazione: (2026)
• Crosslinked Fibrin Fragment (X‐ FIB ) as a Biomarker for Endotype Differentiation and Response to Omalizumab Treatment in Chronic Spontaneous Urticaria
  di: Helena Port, et al.
  Pubblicazione: (2025)
• Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria
  di: Melek Cihanbeylerden, et al.
  Pubblicazione: (2024)